2-甲基-4-甲基氨基异吲哚-1,3-二酮 | 2762-19-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: 2-甲基-4-甲基氨基异吲哚-1,3-二酮
• 英文名称: 2-methyl-4-methylamino-isoindole-1,3-dione
• 英文别名: 3-monomethylamino-N-methylphthalimide；3-Monomethylamino-N-methyl-phthalimid；3-Methylamino-N-methyl-phthalimid；1H-Isoindole-1,3(2H)-dione, 2-methyl-4-(methylamino)-；2-methyl-4-(methylamino)isoindole-1,3-dione
• CAS: 2762-19-8
• 化学式: C₁₀H₁₀N₂O₂
• 分子量: 190.202
• InChiKey: SMGQXSVQVAPSKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-methyl-2,4-dioxo-1,4-dihydro-2H-benz[d][1,3]oxazine-5-carboxylic acid methyl ester 、 甲胺 在 乙醇 作用下， 生成 2-甲基-4-甲基氨基异吲哚-1,3-二酮
  参考文献：
  名称：

  Quinazolines. IX. A Study of an Unusual Reaction of 5-Diazoacetyl-1,3-dimethyl-2,4-quinazolinedione¹

  摘要：

  DOI：

  10.1021/ja01167a010

文献信息

• [EN] QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS<br/>[FR] DERIVES DE QUINOLEINE UTILISES EN TANT QU'INHIBITEURS DE LA PHOSPHODIESTERASE
  申请人：GLAXO GROUP LTD

  公开号：WO2004103998A1

  公开（公告）日：2004-12-02

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20 and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了化合物的新结构，其化学式为（I）或其药用盐，其中R1、R2、R19、R20和R34如规范中所述，以及制备这些化合物的方法、含有它们的配方和它们在治疗炎症性疾病中的用途。
• Quinoline derivatives as phosphodiesterase inhibitors
  申请人：Baldwin Robert Ian

  公开号：US20070142373A1

  公开（公告）日：2007-06-21

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R 1 , R 2, R 19, R 20, and R 34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了新型化合物(I)的公式或其药学上可接受的盐，其中R1、R2、R19、R20和R34如规范所述，制备它们的过程，含有它们的配方以及它们在治疗炎症性疾病中的用途。
• Quinoline Derivatives As Phosphodiesterase Inhibitors
  申请人：Baldwin Ian Robert

  公开号：US20090312325A1

  公开（公告）日：2009-12-17

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了一种新的化合物式(I)或其药学上可接受的盐，其中R1、R2、R19、R20和R34如规范所述，以及制备它们的过程、含有它们的制剂以及它们在治疗炎症性疾病方面的用途。
• Quinoline derivatives as phosphodiesterase inhibitors
  申请人：GLAXO GROUP LIMITED

  公开号：EP1944305A1

  公开（公告）日：2008-07-16

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20 and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了式 (I) 的新型化合物或其药学上可接受的盐类（其中 R1、R2、R19、R20 和 R34 如说明书所述）、制备它们的工艺、含有它们的制剂以及它们在治疗炎症性疾病中的用途。
• QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1633748B1

  公开（公告）日：2008-03-05